Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASCO Annual Meeting Coverage

Set Alert for ASCO Coverage

The American Society of Clinical Oncology annual meeting for 2024 takes place in Chicago from 31 May to 4 June. This page is your one-stop shop for all of Scrip's conference coverage, including preview and post-meeting analysis. You can also find archive content from previous meetings here.

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

CAR-T Cancer

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO Clinical Trials

ASCO 2024 Wrap-Up Podcast

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting. 

ASCO Cancer

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

Legislation ASCO

ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer

In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.

ASCO China

ASCO: Favorable Data For J&J Combo in 1L NSCLC Gain Attention

Positive new and updated data at ASCO for Rybrevant plus lazertinib could position the combo more strongly against Tagrisso in the first-line treatment of high-risk, EGFR-mutated non-small lung cancer. 

ASCO Clinical Trials

ASCO: Regeneron Shows Early Bispecific Antibody Efficacy In Hard-To-Treat Colorectal Cancer

Scrip talked to Regeneron at ASCO about REGN7075 and Regeneron’s bispecific development strategy in solid tumors.

ASCO Business Strategies

ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T

Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.

Clinical Trials Companies

ASCO: Ivonescimab A New Challenger To Keytruda In 1L, PD-L1-High NSCLC?

Backed by strong progression-free survival results from the China-only, head-to-head HARMONi-2 trial, Akeso/Summit’s ivonescimab could be set to become a global contender against established standard of care Keytruda in first-line, PD-L1-high non-small cell lung cancer.

China Clinical Trials

ASCO Roundup: Looking For The Future Of Cancer Research

As the American Society of Clinical Oncology annual meeting drew to a close, Scrip spoke with industry execs about staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.

ASCO Cancer

ASCO: As FDA’s Zolbetuximab Decision Looms, Astellas Looks To Meet Testing Challenge

Scrip sat down with Astellas chief medical officer Tadaaki Taniguchi to talk about the drug maker’s plans for taking its Claudin18.2-targeting drug to the US market.

ASCO Cancer

ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data

Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.

ASCO Business Strategies

ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC

Excluding PD-1 inhibitors in its combination strategy for oncology, preliminary results from GenFleet’s Phase II KROCUS study presented at ASCO demonstrate promising efficacy for fulzerasib plus cetuximab in the first-line treatment of KRAS G12C-mutated, advanced non-small cell lung cancer.

China ASCO

ASCO: Legend/J&J Explore Carvykti In Community

The companies presented data from CARTITUDE-4 in functional high-risk disease, which has a poorer prognosis, while they are also piloting a program to expand Carvykti’s geographic reach.


ASCO: Enhertu’s Empire Expands

“Transformative” data could move Daiichi Sankyo and AstraZeneca’s conjugate into ultralow HER2 expressers, and allow its use ahead of chemo in breast cancer.

ASCO Clinical Trials

ASCO: NADINA Supports Neoadjuvant IO For Melanoma

The trial offers proof of concept for using Opdivo plus Yervoy as neoadjuvant treatment in melanoma; BMS notes a registrational trial is needed, but it is not clear which IO drugs will advance. 

ASCO Cancer
See All